article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.

FDA 119
article thumbnail

Amgen opens its most advanced manufacturing facility to date

European Pharmaceutical Review

The facility has been designed to meet the highest environmental sustainability standards, to help Amgen’s reach its target of carbon neutrality in all operations by 2027, the company noted. The post Amgen opens its most advanced manufacturing facility to date appeared first on European Pharmaceutical Review.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New US fill finish facility receives $4.1 billion investment

European Pharmaceutical Review

This is compared to the company’s $3.9 (DKK Completion is expected between 2027 and 2029. Currently, worldwide, the pharmaceutical company has a five production sites in Denmark, US, France, Brazil and China, the company noted. billion investment appeared first on European Pharmaceutical Review.

article thumbnail

Eli Lilly plans to invest $450m at production site in Research Triangle Park

Pharmafile

US-based pharmaceutical company, Eli Lilly and Company, has announced plans to invest $450m in its manufacturing facilities at Research Triangle Park in North Carolina, US. The facility is expected to become operational in 2027 and will create over 100 new jobs for manufacturing personnel. read more

article thumbnail

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen

pharmaphorum

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Novo Nordisk investing in rare disease with major new manufacturing site

European Pharmaceutical Review

Novo Nordisk is planning a new investment, which marks the first time this millennium that the pharmaceutical company breaks ground in Denmark by establishing a new production site. Construction is expected to be finished in 2027, the pharma company confirmed. A total of DKK 8.5

article thumbnail

After rebuffing Biogen, Sage pairs off with Supernus

pharmaphorum

Skip to main content Monday 16 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)